Anatara Lifesciences Ltd (ANR) AI Stock Analysis

• Market Cap: AU$3.76M
• Dividend Yield: N/A
• Average Volume (3M): 759.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.19
• Revenue Growth: N/A
• EPS Growth: 1.03%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 313,590,330
• 10 Day Avg. Volume: 1,527,300
• 30 Day Avg. Volume: 759,886
• PEG Ratio: 0.25
• Price to Book (P/B): 1.91
• Price to Sales (P/S): 1.06
• P/FCF Ratio: -0.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: AU$0.01 ▲(20.00% Upside)

The score is held down primarily by weak financial performance—persistent losses, negative margins, shrinking equity, and worsening cash burn—indicating ongoing reliance on external funding. Technical indicators also point to bearish momentum (very low RSI and negative MACD). Valuation is neutral-to-mixed because the negative P/E reflects unprofitability and dividend yield data is unavailable.

Positive Factors

Product pipeline (GaRP)

Anatara's focus on GaRP and orally delivered gastrointestinal therapeutics reflects a clear, durable R&D-to-commercialisation franchise. Clinical/validation work and partnering/commercialisation planning create a defined pathway to scale, supporting long-term value if trials and partnerships advance.

Revenue rebound FY2025

A ~287% revenue rebound to ~0.97M indicates emerging commercial traction and product uptake. Durable momentum at the top line, even from a small base, reduces execution risk versus stagnant sales and underpins the potential to achieve scale economies and improved margins as commercialisation progresses.

Moderate absolute debt

Absolute debt of ~0.41M implies limited interest servicing burden relative to many peers, preserving short-to-medium-term operational flexibility. Moderate leverage supports the company’s capacity to pursue additional funding or partnerships without heavy fixed financing obligations that would stress cash flow.

Negative Factors

Negative gross margins

Sustained negative gross profit shows core product costs exceed revenues, a structural profitability issue. Without durable COGS reductions, price increases, or significant volume-driven efficiencies, the business cannot convert revenue into sustainable profits, threatening long-term viability.

Worsening cash burn

Deepening negative operating and free cash flows (worse to -2.27M) indicate reliance on external capital. Persistent cash burn reduces runway, raises dilution risk, and constrains sustained R&D and commercial activities, making long-term execution dependent on successful fundraising or partner funding.

Declining equity base

Equity erosion to ~0.54M from ~1.36M reflects accumulated losses and shrinks balance-sheet resilience. Lower equity limits capacity to absorb shocks, reduces borrowing headroom, and increases the likelihood of dilutive financing or unfavorable deal terms, elevating medium-term solvency risk.

Anatara Lifesciences Ltd Business Overview & Revenue Model

Company Description

Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry water. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.

How the Company Makes Money

Anatara Lifesciences Ltd generates revenue through the development and commercialization of its proprietary health solutions. The company earns money by licensing its technologies and products to pharmaceutical and biotech companies, which in turn manufacture and distribute these solutions to the market. Anatara may also engage in strategic partnerships and collaborations to enhance its product development and market reach. Additionally, the company could receive milestone and royalty payments based on the success and sales of its licensed products.

Anatara Lifesciences Ltd Financial Statement Overview

Summary

Despite a sharp FY2025 revenue rebound (~287% YoY), the business remains structurally weak: negative gross profit (costs exceeding revenue), large ongoing losses (FY2025 net loss ~1.95M; net margin ~-202%), shrinking equity (~0.54M vs ~1.36M prior year), and worsening cash burn (FY2025 operating/free cash flow about -2.27M vs ~-1.25M). Debt remains moderate in absolute terms (~0.41M), but leverage has risen (debt-to-equity ~0.76) as equity declines.

Income Statement

Revenue rebounded in FY2025 (up ~287% YoY to ~0.97M), but the core earnings profile remains weak. Gross profit is negative in FY2024–FY2025 (negative gross margin), indicating costs exceed revenue, and losses remain substantial (FY2025 net loss ~1.95M; net margin about -202%). While the net loss is smaller than several prior years, profitability has not stabilized and margins remain deeply negative.

Balance Sheet

Leverage is still moderate with debt at ~0.41M and debt-to-equity at ~0.76 in FY2025, but this is a notable increase from recent years with minimal debt. Equity has also declined sharply (to ~0.54M in FY2025 from ~1.36M in FY2024), reflecting ongoing losses and reducing balance-sheet flexibility. Returns on equity are deeply negative, signaling continued value dilution for shareholders.

Cash Flow

Cash generation is a key pressure point: operating cash flow and free cash flow are consistently negative across all periods, and FY2025 burn worsened to about -2.27M versus ~-1.25M in FY2024. Cash outflows are running larger than reported losses (operating cash flow to net income is negative), highlighting limited self-funding capacity and ongoing reliance on external capital to sustain operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	746.36K	969.46K	644.03K	0.00	0.00	0.00
Gross Profit	-511.80K	-633.97K	-748.91K	-24.76K	-24.68K	-6.26K
EBITDA	-1.56M	-1.96M	-1.46M	-3.21M	-2.97M	-3.01M
Net Income	-1.56M	-1.95M	-1.45M	-2.02M	-2.53M	-2.00M
Balance Sheet
Total Assets	1.15M	1.15M	1.67M	1.42M	1.77M	4.33M
Cash, Cash Equivalents and Short-Term Investments	101.36K	101.36K	982.11K	401.18K	1.17M	3.43M
Total Debt	407.42K	407.42K	0.00	0.00	65.80K	79.92K
Total Liabilities	612.42K	612.42K	306.85K	494.83K	403.35K	496.67K
Stockholders Equity	535.97K	535.97K	1.36M	924.54K	1.36M	3.83M
Cash Flow
Free Cash Flow	-1.59M	-2.27M	-1.25M	-2.26M	-2.24M	-2.10M
Operating Cash Flow	-1.59M	-2.27M	-1.25M	-2.26M	-2.23M	-2.10M
Investing Cash Flow	0.00	0.00	50.00K	-1.73K	-56.56K	-3.98K
Financing Cash Flow	1.39M	1.39M	1.83M	1.49M	-22.44K	2.85M

Anatara Lifesciences Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CMB	48 Neutral	AU$13.78M	-2.33	-166.70%	―	―	―
ANR	47 Neutral	AU$3.76M	-1.25	-205.70%	―	―	1.03%
ADO	44 Neutral	AU$40.91M	-5.60	-159.86%	―	110.44%	35.90%
AVE	44 Neutral	AU$36.73M	-9.09	-143.71%	―	306.88%	―
HXL	40 Underperform	AU$2.17M	-4.33	-28.49%	―	―	46.43%
1AD	37 Underperform	AU$12.75M	-1.61	-628.72%	―	―	31.87%

Anatara Lifesciences Ltd Corporate Events

Anatara Flags Promising Anti-Obesity Data as Capital Raise Bolsters Pipeline Plans

Anatara Lifesciences reported that interim pre-clinical data from its Anti-Obesity Project at the University of Newcastle identified a lead candidate compound, AOC, which showed statistically significant effects in attenuating post-semaglutide weight regain and reducing visceral (perigonadal) fat in a mouse model of diet-induced obesity, supporting its potential as an oral complementary therapy to help maintain weight loss after GLP-1 treatments. Completion of detailed mechanism-of-action studies has been delayed by international supply issues with a key testing kit, with results now expected in February 2026, after which Anatara will decide on further development and commercialisation steps; during the quarter the company also completed a $1.2 million capital raise, ended with $1.035 million in cash, advanced publication-ready analysis of its GaRP gastrointestinal health program, and signalled its intention to continue evaluating strategic opportunities across the junior healthcare sector while maintaining tight financial control.

The most recent analyst rating on (AU:ANR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Anatara Lifesciences Ltd stock, see the AU:ANR Stock Forecast page.

Anatara Lifesciences Reports Promising Results in Anti-Obesity Project

Anatara Lifesciences Ltd has reported promising pre-clinical results for its Anti-Obesity Project, with the candidate compound AOC showing significant potential in managing weight reduction and controlling weight gain after cessation of weight loss treatments. Although the Mechanism of Action studies have faced delays due to international supply issues, the company remains committed to advancing its research and exploring further commercial opportunities. The project aims to develop an oral complementary medication to assist in weight management, and Anatara is actively pursuing business development discussions to capitalize on these findings.

Anatara Lifesciences Announces Director’s Interest Change

Anatara Lifesciences Limited has announced a change in the director’s interest notice concerning Dr. David Brookes. The company disclosed that Dr. Brookes has disposed of 932,143 unlisted options, with no new securities acquired. This change reflects adjustments in Dr. Brookes’ holdings, which include both direct and indirect interests through various trusts and superfunds. The announcement is part of the company’s compliance with ASX listing rules, ensuring transparency in the director’s financial interests.

Anatara Lifesciences Announces Cessation of Securities

Anatara Lifesciences Ltd announced the cessation of 27,749,784 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perception regarding the company’s financial strategies.

Anatara Lifesciences Director Increases Stake

Anatara Lifesciences Ltd announced a change in the director’s interest, with Dr. David Brookes acquiring additional shares through entities Tarandi and Dahlbrook Family Trust. This acquisition, valued at $40,000, reflects a strategic move that could influence the company’s market positioning and stakeholder confidence.

Anatara Lifesciences Issues New Unquoted Equity Securities

Anatara Lifesciences Ltd announced the issuance of 4,000,000 unquoted equity securities in the form of options expiring on November 26, 2028, with an exercise price of $0.025. This move is part of previously announced transactions and reflects the company’s ongoing efforts to strengthen its financial position and support its strategic initiatives, potentially impacting its market presence and stakeholder interests.

Anatara Lifesciences Completes Tranche 2 Share Placement

Anatara Lifesciences Ltd has completed the final allocation of shares under Tranche 2 of its two-tranche placement, issuing 66,352,417 ordinary shares. Additionally, 4,000,000 unlisted options were allotted to the Lead Manager, exercisable at $0.025 each and expiring in three years. This strategic move is expected to bolster Anatara’s financial position, supporting its ongoing product development and market expansion efforts.

Anatara Lifesciences Announces Cessation of Securities

Anatara Lifesciences Ltd has announced the cessation of 300,000 securities under the ASX code ANRAQ due to the expiry of options without exercise or conversion. This development may affect the company’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market positioning.

Anatara Lifesciences Issues Investment Disclaimer

Anatara Lifesciences Ltd has issued a disclaimer regarding the information provided in their recent presentation, emphasizing that it should not be considered personal investment advice. The company stresses the importance of consulting a professional investment adviser before making any investment decisions based on the presentation. The release highlights that the information is based on sources deemed reliable, but no guarantees are made regarding its accuracy or completeness, and the company disclaims liability for any potential losses incurred by relying on the presentation.

Anatara Lifesciences Updates Shareholders on 2025 Progress and Future Prospects

Anatara Lifesciences faced challenges in 2025, notably with the GaRP-IBS Phase II trial not meeting its primary efficacy endpoint, although it showed significant symptom improvement. The company is optimistic about the potential commercial viability of GaRP, with forthcoming publications expected to aid in commercial considerations. Additionally, the Anti-Obesity project is progressing, with proof-of-concept studies nearing completion and preliminary findings being encouraging. Anatara continues to explore new opportunities, emphasizing products that address unmet needs, and remains committed to enhancing shareholder value.